Eli Lilly Q2 FY26: where the revenue came from and where it went
The whole income statement of Eli Lilly for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2026
- Reported
- Aug 5, 2026
Revenue$23.0B
+48% year over year
Gross profit$19.7B
86% margin
Operating profit$9.0B
39% margin
Net profit$7.1B
31% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 23.0 | 100% | +48% |
| Mounjaro | 9.9 | 43% | +91% |
| Zepbound | 4.9 | 22% | +46% |
| Other revenue | 2.1 | 9% | |
| Verzenio | 1.5 | 6% | −1% |
| Jardiance | 1.2 | 5% | |
| Trulicity | 1.2 | 5% | +12% |
| Other oncology | 1.1 | 5% | +19% |
| Cardiometabolic health | 1.0 | 5% | +5% |
| Cost of revenue | −3.3 | 14% | |
| Gross profit | 19.7 | 86% margin | +2pp |
| SG&A | −3.4 | 15% | −3pp |
| Other | −7.3 | 32% | |
| Operating profit | 9.0 | 39% margin | −5pp |
| Other income, net | 0.3 | ||
| Tax | −2.2 | ||
| Net profit | 7.1 | 31% margin | −6pp |
123 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest